Benoit You (Benoît You)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 41

Top Topics

Patient Reported

Metastatic Breast Cancer

Top Venues

JCO clinical cancer informatics

Journal of gynecologic oncology

Breast cancer research and treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Pauline Corbaux, Olivier Colomban, Aurore Carrot, Benoit You
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer. Biomarkers in medicine (2024)
Pauline Corbaux, Olivier Colomban, Aurore Carrot, Benoit You
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer. Biomarkers in medicine 18 (10-12) (2024)
Pauline Corbaux, Olivier Colomban, Aurore Carrot, Benoit You
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer. Biomarkers in medicine 18 (10-12) (2024)
Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". Journal of gynecologic oncology 35 (3) (2024)
Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". Journal of gynecologic oncology 35 (3) (2024)
Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". Journal of gynecologic oncology (2024)
Pauline Corbaux, Gilles Freyer, Olivier Glehen, Benoit You, Naoual Bakrin, Audrey Gelot, David Dayde, Christophe Sajous, Max Piffoux, Julien Péron, Gaelle Lescuyer, Léa Payen, Vahan Kepenekian
Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Pauline Corbaux, Gilles Freyer, Olivier Glehen, Benoit You, Naoual Bakrin, Audrey Gelot, David Dayde, Christophe Sajous, Max Piffoux, Julien Péron, Gaelle Lescuyer, Léa Payen, Vahan Kepenekian
Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". Journal of gynecologic oncology 35 (3) (2024)
Pauline Corbaux, Olivier Colomban, Aurore Carrot, Benoit You
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer. Biomarkers in medicine 18 (10-12) (2024)
Aurore Carrot, Stéphane Oudard, Olivier Colomban, Karim Fizazi, Denis Maillet, A Oliver Sartor, Gilles Freyer, Benoit You
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA. JCO clinical cancer informatics 8 (2024)
Claire Lattard, Chloé Herledan, Thibaut Reverdy, Gabriel Antherieu, Anne-Gaelle Caffin, Marie-Anne Cerfon, Magali Maire, Marine Rivat, Stéphanie France, Hervé Ghesquières, Benoit You, Gilles Freyer, Florence Ranchon, Catherine Rioufol
Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program. The oncologist (2024)
Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". Journal of gynecologic oncology 35 (3) (2024)
Aurore Carrot, Stéphane Oudard, Olivier Colomban, Karim Fizazi, Denis Maillet, A Oliver Sartor, Gilles Freyer, Benoit You
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA. JCO clinical cancer informatics 8 (2024)
Olivier Colomban, Andrew Clamp, Adrian Cook, Iain A McNeish, Benoit You
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial. JCO clinical cancer informatics 7 (2023)
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, Isabelle L Ray-Coquard, Christelle De La Fouchardière, François Bertucci, Anthony Goncalves, Carlos Gomez-Roca, Benoit You, Valéry Attignon, Sandrine Boyault, Philippe A Cassier, Armelle Dufresne, Séverine Tabone-Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenaël Garin, Jean Yves Blay, David Pérol
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort. Cancers 15 (13) (2023)
Olivier Colomban, Andrew Clamp, Adrian Cook, Iain A McNeish, Benoit You
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial. JCO clinical cancer informatics 7 (2023)
Olivier Colomban, Andrew Clamp, Adrian Cook, Iain A McNeish, Benoit You
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial. JCO clinical cancer informatics 7 (2023)
Olivier Colomban, Andrew Clamp, Adrian Cook, Iain A McNeish, Benoit You
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial. JCO clinical cancer informatics 7 (2023)
Yvette Drew, Jae-Weon Kim, Richard T Penson, David M O'Malley, Christine Parkinson, Patricia Roxburgh, Ruth Plummer, Seock-Ah Im, Martina Imbimbo, Michelle Ferguson, Ora Rosengarten, Neeltje Steeghs, Min Hwan Kim, Einav Nili Gal-Yam, Daliah Tsoref, Jae-Hoon Kim, Benoit You, Maja J A de Jonge, Roy I Lalisang, Eelke H Gort, Sara Bastian, Kassondra Meyer, Laura Feeney, Nigel Baker, Mei-Lin Ah-See, Susan M Domchek, Susana Banerjee
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Alicja Puszkiel, Benoit You, Léa Payen, Jonathan Lopez, Jérôme Guitton, Pascal Rousset, Juliette Fontaine, Julien Péron, Denis Maillet, Sophie Tartas, Nathalie Bonnin, Veronique Trillet-Lenoir, Olivier Colomban, Diane Augu-Denechere, Gilles Freyer, Michel Tod
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial. Cancer chemotherapy and pharmacology (2023)
Eleni Karamouza, Rosalind M Glasspool, Caroline A Kelly, Liz-Anne Lewsley, Karen Carty, Gunnar B Kristensen, Josee-Lyne Ethier, Tatsuo Kagimura, Nozomu Yanaihara, Sabrina Chiara Cecere, Benoit You, Ingrid A Boere, Eric Pujade-Lauraine, Isabelle L Ray-Coquard, Cécile Proust-Lima, Xavier Paoletti
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. Cancers 15 (6) (2023)
Judith Balmaña, Peter Andreas Fasching, Fergus J Couch, Suzette Delaloge, Sana Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Goncalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena V Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, A Anton Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, null null
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment 204 (2) (2023)
Olivier Colomban, Andrew Clamp, Adrian Cook, Iain A McNeish, Benoit You
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial. JCO clinical cancer informatics 7 (2023)
Judith Balmaña, Peter Andreas Fasching, Fergus J Couch, Suzette Delaloge, Sana Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Goncalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena V Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, A Anton Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, null null
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment (2023)
Romain Varnier, Alicja Puszkiel, Michel Tod, Sara Calattini, Lea Payen, Jonathan Lopez, Jérome Guitton, Vérane Schwiertz, Juliette Fontaine, Julien Peron, Denis Maillet, Sophie Tartas, Nathalie Bonnin, Olivier Colomban, Diane Augu-Denechere, Gilles Freyer, Benoit You
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors. Cancer chemotherapy and pharmacology (2023)
Judith Balmaña, Peter Andreas Fasching, Fergus J Couch, Suzette Delaloge, Sana Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Goncalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena V Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, A Anton Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, null null
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment 204 (2) (2023)
Eleni Karamouza, Rosalind M Glasspool, Caroline A Kelly, Liz-Anne Lewsley, Karen Carty, Gunnar B Kristensen, Josee-Lyne Ethier, Tatsuo Kagimura, Nozomu Yanaihara, Sabrina Chiara Cecere, Benoit You, Ingrid A Boere, Eric Pujade-Lauraine, Isabelle L Ray-Coquard, Cécile Proust-Lima, Xavier Paoletti
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. Cancers 15 (6) (2023)
Judith Balmaña, Peter Andreas Fasching, Fergus J Couch, Suzette Delaloge, Sana Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Goncalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena V Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, A Anton Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, null null
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment 204 (2) (2023)
Judith Balmaña, Peter Andreas Fasching, Fergus J Couch, Suzette Delaloge, Sana Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Goncalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena V Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, A Anton Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, null null
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment 204 (2) (2023)
Benoit You, Christopher Purdy, Larry J Copeland, Elizabeth M Swisher, Michael A Bookman, Gini F Fleming, Robert L Coleman, Leslie M Randall, Krishnansu S Tewari, Bradley J Monk, Robert S Mannel, Joan L Walker, Fabio Cappuccini, David E Cohn, Mahvish Muzaffar, David G Mutch, Andrea E Wahner Hendrickson, Lainie Martin, Olivier Colomban, Robert A Burger
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (34) (2022)
Bastien Collomb, Amélie Dubromel, Anne Gaëlle Caffin, Chloé Herledan, Virginie Larbre, Amandine Baudouin, Ariane Cerutti, Laurence Couturier, Magali Maire, Lionel Karlin, Delphine Maucort-Boulch, Laure Huot, Stéphane Dalle, Emmanuel Bachy, Hervé Ghesquieres, Gilles Salles, Sébastien Couraud, Benoit You, Gilles Freyer, Véronique Trillet-Lenoir, Florence Ranchon, Catherine Rioufol
Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. Cancers 14 (3) (2022)
Benoit You, Vasudha Sehgal, Balakrishna Hosmane, Xin Huang, Peter J Ansell, Minh H Dinh, Katherine Bell-McGuinn, Xizhi Luo, Gini F Fleming, Michael L Friedlander, Michael A Bookman, Kathleen M Moore, Karina Dahl Steffensen, Robert L Coleman, Elizabeth M Swisher
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Guy Jerusalem, Yeon Hee Park, Sara Alsterlind Hurvitz, Shanu Modi, Fabrice Andre, Ian E Krop, Xavier Gonzalez, Benoit You, Cristina Saura, Sung-Bae Kim, Cynthia R Osborne, Rashmi K Murthy, Lorenzo Gianni, Toshimi Takano, Yali Liu, Jillian Cathcart, Caleb Lee, Christophe Perrin
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer discovery 12 (12) (2022)
Fabrice Andre, Thomas Filleron, Maud Kamal, Fernanda Mosele, Monica Arnedos, Florence Dalenc, Marie-Paule Sablin, Mario Campone, Hervé Bonnefoi, Claudia Lefeuvre-Plesse, William Jacot, Florence Coussy, Jean-Marc Ferrero, George Emile, Marie-Ange Mouret-Reynier, Jean-Christophe Thery, Nicolas Isambert, Alice Mege, Philippe Barthelemy, Benoit You, Nawale Hajjaji, Ludovic Lacroix, Etienne Rouleau, Alicia Tran-Dien, Sandrine Boyault, Valery Attignon, Pierre Gestraud, Nicolas Servant, Christophe Le Tourneau, Linda Larbi Cherif, Isabelle Soubeyran, Filippo Montemurro, Alain Morel, Amelie Lusque, Marta Jimenez, Alexandra Jacquet, Anthony Gonçalves, Thomas Bachelot, Ivan Bieche
Genomics to select treatment for patients with metastatic breast cancer. Nature 610 (7931) (2022)
Benoit You, Lilian Van Wagensveld, Michel Tod, Gabe S Sonke, Hugo Mark Horlings, R F P M Kruitwagen, Andreas Du Bois, Frédéric Selle, Timothy Perren, Jacobus Pfisterer, Florence Joly, Adrian Cook, Marie Christine Kaminsky, Kerstin Wollschlaeger, Alain Lortholary, Oliver Tome, Alexandra Leary, Gilles Freyer, Maaike Van Der Aa, Olivier Colomban
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. British journal of cancer 127 (1) (2022)
Aurore Carrot, Reza-Thierry Elaidi, Olivier Colomban, Denis Maillet, Michel Tod, Benoit You, Stephane Marie Oudard
Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/- Docetaxel. Cancers 14 (3) (2022)
Pascal Pujol, Kevin Yauy, Amandine Coffy, Nicolas Duforet-Frebourg, Sana Gabteni, Jean-Pierre Daurès, Frédérique Penault Llorca, Frederic Thomas, Kevin Hughes, Clare Turnbull, Virginie Galibert, Chloé Rideau, Carole Corsini, Laetitia Collet, Benoit You, David Genevieve, Nicolas Philippe
Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation. Cancers 14 (13) (2022)
Benoit You, Patrick Robelin, Michel Tod, Christophe Louvet, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Michel Fabbro, Christophe Desauw, Nathalie Bonichon-Lamichhane, Jean-Emmanuel Kurtz, Philippe Follana, Marianne Leheurteur, Francesco Del Piano, Gwenaël Ferron, Gaëtan De Rauglaudre, Isabelle Ray-Coquard, Pierre Combe, Annick Chevalier-Place, Florence Joly, Alexandra Leary, Eric Pujade-Lauraine, Gilles Freyer, Olivier Colomban
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (17) (2020)
Olivier Colomban, Michel Tod, Julien Peron, Timothy J Perren, Alexandra Leary, Adrian D Cook, Christophe Sajous, Gilles Freyer, Benoit You
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). JNCI cancer spectrum 4 (3) (2020)
Maxime Frelaut, Nienke De Glas, Ignacio Zapardiel, Orit Kaidar-Person, Maria Kfoury, Benoit You, Susana Banerjee, Etienne Brain, Claire Falandry, Manuel J Rodrigues
Are Older Patients with Cervical Cancer Managed Differently to Younger Patients? An International Survey. Cancers 11 (12) (2019)